PNPLA2

Patatin-like phospholipase domain-containing protein 2 · Q96AD5 · PNPLA2 on Sugi Atlas →

1,402 patent compounds predicted against PNPLA2, 1,160 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Azd-1208 (SCHEMBL1580644)	1.00	2/20
Azd-1208 (SCHEMBL1580646)	1.00	2/20
SCHEMBL1580546	0.74	2/20
SCHEMBL1580547	0.74	2/20
SCHEMBL1580738	0.74	2/20
SCHEMBL1580740	0.74	2/20
SCHEMBL1581733	0.74	2/20
SCHEMBL1581735	0.74	2/20
SCHEMBL1581737	0.74	2/20
Hydrochloric Acid (SCHEMBL2420968)	0.72	2/20
Hydrochloric Acid (SCHEMBL2420971)	0.72	2/20
Hydrochloric Acid (SCHEMBL2420975)	0.72	2/20
Hydrochloric Acid (SCHEMBL2427790)	0.72	2/20
Hydrochloric Acid (SCHEMBL2427794)	0.72	2/20
Hydrochloric Acid (SCHEMBL2427795)	0.72	2/20
Hydrochloric Acid (SCHEMBL2427800)	0.72	2/20
SCHEMBL1580525	0.71	2/20
SCHEMBL1580527	0.71	2/20
SCHEMBL1580660	0.70	2/20
SCHEMBL1580665	0.70	2/20

Clinical trials — most relevant to PNPLA2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency	PHASE3	COMPLETED
Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease	PHASE2	RECRUITING
Cholic Acid for Hepatic Steatosis in Lipodystrophy	PHASE2	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Insulin Regulation of Lipolysis and Lipolysis Proteins	EARLY_PHASE1	RECRUITING
Liver Damage and Cardiometabolic Disorders in NAFLD	nan	RECRUITING
Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease	nan	UNKNOWN
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.	nan	UNKNOWN
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With MASLD.	nan	ENROLLING_BY_INVITATION
Evaluation of Risk of hEpatocellular Carcinoma	nan	RECRUITING
Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease	nan	COMPLETED
Human Liver ORganoids as a Model to Study the Development of Non-Alcoholic SteatOhepatitis (NASH)	nan	RECRUITING
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)	nan	RECRUITING
Familial Partial Lipodystrophy Study	nan	COMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects	nan	UNKNOWN
Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD	nan	RECRUITING
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes	nan	RECRUITING
Metabolic Flexibility, Gut Microbiota, Healthy Diet and Exercise in NAFLD on Genetics Base	nan	COMPLETED
Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects)	nan	UNKNOWN
Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With Classic Polycystic Ovary Syndrome (PCOS)	nan	NOT_YET_RECRUITING
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV	nan	NOT_YET_RECRUITING
Liver Fat as a Dietary Target for Treating Cardiometabolic Disorders in Prediabetes and Type 2 Diabetes	nan	COMPLETED
for Adipose Tissue DIabetes VAriants (fATDIVA)	nan	COMPLETED
Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)	nan	COMPLETED
Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase.	nan	UNKNOWN
Liver, Diet and Genetic Background	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Epidemiology of Atherosclerosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PNPLA2 binder may also engage these)

Protein	Name	Similarity
P0C548	—	1.000	P0C548 →
Q8BJ56	—	1.000	Q8BJ56 →
Q9NST1	—	0.998	Q9NST1 →
Q2KI18	—	0.997	Q2KI18 →
Q91WW7	—	0.995	Q91WW7 →
Q32LZ8	—	0.993	Q32LZ8 →
P54310	—	0.985	P54310 →
Q50L41	—	0.984	Q50L41 →
Q68DD2	—	0.983	Q68DD2 →
Q68J42	—	0.983	Q68J42 →
Q9R101	—	0.983	Q9R101 →
Q8N8W4	—	0.982	Q8N8W4 →
D3YWQ0	—	0.981	D3YWQ0 →
O75064	—	0.981	O75064 →
KCNH3	Voltage-gated inwardly rectifying potassium channel KCNH3	0.980	landscape →
D3ZEY4	—	0.980	D3ZEY4 →
Q3V1D5	—	0.980	Q3V1D5 →
Q8K330	—	0.980	Q8K330 →
Q9Y4C4	—	0.980	Q9Y4C4 →
Q7Z6Z6	—	0.980	Q7Z6Z6 →
P49899	—	0.979	P49899 →
Q3TZX8	—	0.979	Q3TZX8 →
Q3MJ16	—	0.979	Q3MJ16 →
O08560	—	0.979	O08560 →
P16386	—	0.979	P16386 →
Q8CFK6	—	0.979	Q8CFK6 →
Q28969	—	0.979	Q28969 →
P48760	—	0.979	P48760 →
F1MAB7	—	0.979	F1MAB7 →
Q8BHW9	—	0.979	Q8BHW9 →